Insider Transactions in Q3 2023 at Iovance Biotherapeutics, Inc. (IOVA)
Insider Transaction List (Q3 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2023
|
Merrill A Mcpeak Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+3.87%
|
$50,000
$5.56 P/Share
|
|
Sep 15
2023
|
Wayne P. Rothbaum Director |
BUY
Open market or private purchase
|
Indirect |
5,000,000
+17.81%
|
$25,000,000
$5.3 P/Share
|
|
Jul 14
2023
|
Igor Bilinsky Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.88%
|
$9,765
$7.76 P/Share
|
|
Jul 14
2023
|
Igor Bilinsky Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+8.95%
|
-
|
|
Jul 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,395
-4.31%
|
$9,765
$7.76 P/Share
|
|
Jul 14
2023
|
Finckenstein Friedrich Graf Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,813
+8.0%
|
-
|
|
Jul 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
8,851
-10.83%
|
$61,957
$7.76 P/Share
|
|
Jul 14
2023
|
Frederick G Vogt Interim CEO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,834
+20.32%
|
-
|